Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case–control study
Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case–control study
复制标题
米那普仑和氟伏沙明的不同作用，特别是对于重度抑郁症和激越抑郁症患者：病例对照研究
DOI：
10.1097/00004850-200203000-00002
复制
发表时间：
2002
影响因子：
2.6
通讯作者：
K. Kanemoto
中科院分区：
文献类型：
--
作者：
T. Fukuchi;K. Kanemoto
我们尝试使用17项汉密尔顿抑郁评定量表（HDRS）比较米那普仑和氟伏沙明在202例门诊抑郁症患者中的抗抑郁疗效。特别注意的反应性的差异作为抑郁症的严重程度和个人HDRS因素的函数。因此，虽然总体上未发现治疗组之间的显著差异，但米那普仑记录的阳性反应（总评分较基线降低50%或更多）显著多于基线HDRS总评分大于19分的氟伏沙明接受者。此外，有一个显着的差异，有利于米那普仑的“激越”和“失眠”因素的反应。在两个治疗组中，三环类抗抑郁药特有的不良事件（如口干、便秘、嗜睡和体位性低血压）的发生率均较低。虽然氟伏沙明组主要主诉上消化道疾病，如上腹部不适，但仅米那普仑组报告了泌尿系统并发症和心悸。总之，我们认为，米那普仑是首选选择性5-羟色胺再摄取抑制剂用于治疗抑郁症患者的激越以及严重的抑郁症患者。
We attempted to compare the antidepressant efficacy of milnacipran and fluvoxamine in 202 outpatients with major depression, using the 17-item Hamilton Depression Rating Scale (HDRS). Special attention was paid to the difference of responsiveness as a function of the severity of depression and individual HDRS factors. As a result, while no significant difference between the treatment groups was found overall, a positive response (50% or more decrease in total score from the baseline) was recorded significantly more often with milnacipran than fluvoxamine recipients whose baseline HDRS total score was greater than 19 points. Furthermore, there was a significant difference of response for the ‘agitation’ and ‘insomnia’ factors in favour of milnacipran. In both treatment groups, the incidence of adverse events, characteristic of tricyclic antidepressants such as dry mouth, constipation, somnolence and postural hypotension, was low. While complaints concerning the upper intestinal tract, such as epigastric distress, were predominant in the fluvoxamine group, urological complications and palpitations were reported only in the milnacipran group. In conclusion, we suggest that milnacipran is preferred to selective serotonin reuptake inhibitors for the treatment of depressed patients with agitation as well as severely depressed patients.